@SEPA, I think you've hit the nail on the head here - management teams with good track record get the stick from punters who have rode a rough ride with a company and are happy to forget that if stock prices go up. The other side of the coin is that great mgmt are seriously undervalued. The operational hurdles for prescription medication in the US is much more relaxed than in japan, the appetite to medications/therapies and new tech is much greater, you only have to watch NFL for 15 minutes to get 3 drug adds (and at least one will be a viagra variant, another for back pain and i'm sure we'll see sofdra soon)
I agree that howie and the team are the right team to drive bot past that $1.00 mark and beyond, with the know-how of 30 derma products, this is easy pickings with an actual unmet need. GLTAH & DYOR
BOT Price at posting:
37.5¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)